Wanbury reports 88% drop in Q3 FY25 PAT

Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25

Lupin receives EIR from USFDA for its Somerset manufacturing facility

the inspection conducted from January 27 to January 31, 2025

Orchid Pharma's Alathur API facility successfully completes USFDA inspection

The Alathur facility specializes in the production of Cephalosporin antibiotics

Boehringer's zongertinib receives Priority Review from USFDA for the treatment of HER2 mutant advanced non-small cell lung cancer

Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved

Innocan Pharma granted first patent in India for its Liposomal CBD Injection

Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market

IMCD showcases ‘Skinification’ trend at HPCI India 2025

IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care

Sun Pharma amongst top 5% of global pharmaceutical companies in S&P Global Sustainability Yearbook 2025

This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability

Lupin receives “A-” leadership rating from CDP in climate change and water security

This rating reflects Lupin's leadership in environmental transparency and performance

EyeQ upgrades eye care facility in Surat

Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand

Health Minister inaugurates Second AIIMS Oncology Conclave at NCI-AIIMS, Jhajjar